Marker Therapeutics, Inc. (MRKR) Financial Statements (2024 and earlier)

Company Profile

Business Address 4551 KENNEDY COMMERCE DR.
HOUSTON, TX 77032
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11,78242,35121,35243,90461,7475,129
Cash and cash equivalents11,78242,35121,35243,90461,7475,129
Restricted cash and investments  1,146    
Receivables2,40201,000 108 
Prepaid expense2,4352,4852,0581,52614251
Other undisclosed current assets   156  
Total current assets:16,61945,98224,41145,48761,9975,180
Noncurrent Assets
Operating lease, right-of-use asset 5,4809,83010,844455
Property, plant and equipment 12,323  418148 
Other undisclosed noncurrent assets 012,32210,360   
Total noncurrent assets: 17,80322,15321,204873148 
TOTAL ASSETS:34,42268,13545,61546,35962,1445,180
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4,70511,1356,0131,7582,7551,508
Employee-related liabilities2,0551,694323416162
Accounts payable1,6125,1442,9359931,6191,015
Accrued liabilities2,6378941,279337342116
Other undisclosed accounts payable and accrued liabilities4563,042105105378215
Deferred revenue 1,146  
Debt    204 5
Derivative instruments and hedges, liabilities    31499
Due to related parties2,500     
Other liabilities      
Other undisclosed current liabilities 577620389   
Total current liabilities:7,78212,9026,4021,9932,8041,522
Noncurrent Liabilities
Long-term debt and lease obligation:  11,24811,868280  
Liabilities, other than long-term debt 7,039     
Operating lease, liability 7,03911,24811,868280
Other undisclosed noncurrent liabilities  (11,248)(11,868)   
Total noncurrent liabilities: 7,03911,24811,868280  
Total liabilities:14,82124,15018,2702,2732,8041,522
Equity
Equity, attributable to parent19,60143,98627,34544,08659,3413,658
Common stock88351464511
Additional paid in capital447,642442,021383,533371,574365,401161,068
Accumulated deficit(428,049)(398,118)(356,239)(327,533)(306,105)(157,420)
Total equity:19,60143,98627,34544,08659,3413,658
TOTAL LIABILITIES AND EQUITY:34,42268,13545,61546,35962,1445,180

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues9,0141,242467213206200
Revenue, net200
Gross profit:9,0141,242467213206200
Operating expenses(38,959)(40,720)(29,353)(22,742)(148,378)(11,663)
Other undisclosed operating loss      (200)
Operating loss:(29,946)(39,478)(28,886)(22,529)(148,172)(11,663)
Nonoperating income
(Investment Income, Nonoperating)
24861491,083254 
Interest and debt expense      492
Loss from continuing operations:(29,698)(39,472)(28,737)(21,446)(147,918)(11,171)
Loss before gain (loss) on sale of properties:(39,472)(28,737)(21,446)(147,918)(11,171)
Income from discontinued operations      
Other undisclosed net income (loss)(233)(2,407)3118  
Net loss:(29,931)(41,879)(28,706)(21,428)(147,918)(11,171)
Other undisclosed net income (loss) attributable to parent     (40)189
Net loss available to common stockholders, diluted:(29,931)(41,879)(28,706)(21,428)(147,958)(10,982)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(29,931)(41,879)(28,706)(21,428)(147,918)(11,171)
Comprehensive loss, net of tax, attributable to parent:(29,931)(41,879)(28,706)(21,428)(147,918)(11,171)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: